Market
Scenario
The
breast cancer market is expected to witness tremendous growth owing to the
rising prevalence of breast cancer. Other key factors such as the growing
obesity among women, menstrual history, change in sedentary lifestyle, not
having children, socioeconomic factors, and growing consumption of unhealthy
diet are contributing towards the growth of the market. Research suggests that
other factors such as smoking, exposure to chemicals that can lead to cancer,
and working in night shift also may increase the risk of breast cancer.
However, factors such as high cost of diagnostic procedures, expensive treatments,
and side effects associated with breast biopsy procedures are expected to
restrict the market growth during the forecast period.
The
global breast biopsy market is expected to grow significantly during the
forecast period (2018–2023).
A biopsy
is a small operation performed to remove tissues from an area of concern in the
body. Breast biopsy is a procedure that involves testing of small samples of
breast tissues for detecting breast cancer. Breast biopsies are conducted using
minimal invasive biopsy systems, owing to minimal disfigurement and pain.
There are
different types of biopsy procedures depending on the technique, such as core
needle biopsy (CNB), fine needle aspiration biopsy (FNAB), and vacuum-assisted
biopsy (VAB) recommended by the doctor based on the location, size, and other
characteristics of the breast abnormality.
The
increase in the prevalence of breast cancer, especially among women above the
age of 35 during menopause (are more susceptible to breast cancer) and growth
in the awareness regarding breast cancer screening programs drive the market
growth. However, unspecified regulatory issues, infection risks connected with
breast biopsy procedures, and ambiguous reimbursement policies are the factors
limiting the market growth. Additionally, restraints for the market include the
high cost of surgical procedures and risks involved in them. Conversely, the
emergence of technologically-advanced and minimally invasive breast biopsy
devices are expected to provide lucrative opportunities in the untapped market.
Company
Profiles
- Leica Biosystems
- R. Bard Inc.
- NuVue Therapeutics
- Argon Medical Devices, Inc.
- Becton, Dickinson and Company,
- Devicor Medical Products Inc.
- Hologic Inc.
- Argon Medical Devices,
- Cook Medical Incorporated
- Encapsule Medical Devices LLC.
- Johnson & Johnson
- Galini SRL
- Intact Medical Corporation
- Conceptus INC
- Karl Storz GmbH & Co. Kg
- GE Healthcare
Segmentation
The
breast cancer market has been segmented on the basis of product, technique
type, guidance technology, and end-user. On the basis of product, the market
has been classified as biopsy needles, biopsy tables, biopsy wires, and
guidance systems. On the basis of technique type, the market is classified into
fine needle aspiration biopsy, core needle biopsy, biopsy markers, MRI-guided
core needle biopsy, incisional biopsy, excisional biopsy, wire localization,
and sentinel node biopsy. Further, the core needle biopsy subsegment is
segmented into stereotactic core needle biopsy, vacuum-assisted biopsy,
ultrasound-guided core biopsy, and freehand core-needle biopsy. The surgical
biopsy sub-segment is segmented into incisional biopsy and excisional biopsy.
On the basis of guidance technology, the market is classified into
ultrasound-guided, mammography-guided magnetic resonance, CT-guided biopsy, and
other image-guided breast biopsy (PET and thermography). On the basis of end-user,
the market is divided into hospitals, ambulatory surgical centers, diagnostic
centers, and others.
Regional
Market Summary
In the
breast biopsy market, North America is anticipated to account for the largest
market share due to the early adoption of advanced medical technologies and
continuous development by companies operating in cancer diagnostics. The global
breast biopsy market is largely focused on North America and Europe, which is
valued to account for more than 50% of the market share.
The
European market is expected to hold the second largest market share as breast
cancer is most common in the UK and Belgium. According to the Cancer Research
UK in 2015, 55122 new cases of invasive breast cancer were diagnosed.
The
market share in the Asia-Pacific region is also projected to experience growth
in the near future due to access to optimal treatment facilities, growing
demand for advanced technology, better adoption rate, increasing government
initiatives, and rising healthcare expenditure.
The
market in the Middle East and Africa is expected to account for the smallest
share of the global breast biopsy market due to an underdeveloped healthcare
sector, lack of technical knowledge, and poor medical facilities.
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor
Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
...Continued
About
US:
Market
Research Future (MRFR), enable customers to unravel the complexity of various
industries through Cooked Research Report (CRR), Half-Cooked Research Reports
(HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market
Research & Consulting Services.
Contact
Us:
Market
Research Future
Office
No. 528, Amanora Chambers
Magarpatta
Road, Hadapsar,
Pune
- 411028
Maharashtra,
India
Phone:
+1 646 845 9312
Email:
sales@marketresearchfuture.com
No comments:
Post a Comment